Market Overview

Oppenheimer: Teva Is Now Worth $77/Share, More Deals To Come

Share:

Oppenheimer upgraded Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) Tuesday from Perform to Outperform and set a price target of $77.

Analysts Akiva Felt and Angad Verma expected more deals to come following the announcement that the company would acquire Auspex Pharmaceuticals Inc (NASDAQ: ASPX).

The analysts felt the company would "continue rebuilding through M&A, with the capacity for additional smaller deals to build pipeline value, along with a larger deal focused on generics and established branded products."

Felt and Verma thought that Mallinckrodt PLC (NYSE: MNK) would make sense for an acquisition, however, there were "multiple options for Teva" to pursue with numerous events in the pipeline.

teva_deals.png

The $77 price target was based on a DCF valuation discounted at 9 percent through 2020 and a terminal value (0 percent terminal growth) discounted at 10 percent.

The price target also represented a 14.9x multiple on the firm's 2016 EPS estimate of $5.03, "still modestly below other spec-pharma turnaround stories," according to the analysts.

Felt and Verma concluded, "While we wish we had been earlier with the upgrade, we think this turnaround story still has legs."

Shares of Teva recently traded at $62.92, up 0.64 percent.

Latest Ratings for TEVA

DateFirmActionFromTo
Sep 2019Initiates Coverage OnNeutral
Sep 2019MaintainsUnderweight
Aug 2019MaintainsMarket Perform

View More Analyst Ratings for TEVA
View the Latest Analyst Ratings

Posted-In: Akiva Felt Angad Verma OppenheimerAnalyst Color Upgrades Price Target Analyst Ratings

 

Related Articles (MNK + ASPX)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
IINDoughertyAssumes34.0
PNRJefferiesInitiates Coverage On
YYUBSUpgrades
ROKUOppenheimerMaintains155.0
IPHIBank of AmericaMaintains80.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Top Performing Industries For March 31, 2015

Lean Hogs Move Higher